红花黄色素对乳腺癌细胞增殖和迁移的抑制作用及其分子机制

目的 研究红花黄色素 (CY) 对乳腺癌细胞增殖、凋亡、迁移和侵袭的影响以及相关的分子机制.方法 采用CCK-8法检测不同浓度和时间红花黄色素对人乳腺癌细胞MDA-MB-231的抑制作用;采用流式细胞术检测不同浓度红花黄色素对人乳腺癌细胞MDA-MB-231的促凋亡作用;采用Transwell法检测不同浓度红花黄色素对人乳腺癌细胞MDA-MB-231迁移和侵袭的影响;在不同浓度的红花黄色素的干预后, 通过western blot技术检测凋亡相关蛋白Cleaved-Caspase-3和生存相关蛋白p-Akt以及转移相关蛋白MMP2的表达.结果 (1) 红花黄色素对乳腺癌细胞的抑制作用具有浓度依赖性和时间依赖性; (2) 不同浓度的红花黄色素干预能显著促进乳腺癌细胞的凋亡 (P<0.01) ; (3) 不同浓度的红花黄色素干预能显著抑制p-Akt的表达并同时促进Cleaved-Caspase-3的表达; (4) 不同浓度的红花黄色素能够显著抑制乳腺癌细胞的迁移和侵袭能力 (P<0.01) , 并且能够抑制迁移相关蛋白MMP2的表达.结论 红花黄色素能在体外通过激活凋亡通路而促进凋亡, 并能通过抑制MMP2来抑制乳腺癌细胞的转移.红花黄色素是一种潜在的治疗乳腺癌的药物.

The Suppressive Effect of Carthamin Yellow on the Proliferation and Migration of Human Breast Cancer Cells and Its Related Molecular Mechanisms

Objective To study the effect of Carthamin Yellow (CY) on cell proliferation, apoptosis, migration and invasion ability of breast cancer and its related molecular mechanisms. Methods CCK-8 assay was used to detect cell viability of MDA-MB-231 human breast cancer cells by different concentrations of CY at different time;flow cytometry was used to test the apoptosis rate of MDA-MB-231 cells treated by different concentrations of CY and transwell assay was used to investigate the effect of various concentrations of CY on MDA-MB-231 cell migration and invasion.After the intervention of different concentrations of CY on MDA-MB-231 cells, apoptosis-related protein Cleaved-Caspase-3, survival protein p-Akt and metastasis-related protein MMP2 were detected by western blot. Results (1) CY could inhibit the proliferation of MDA-MB-231 cells in a dose-andtime-dependent manner. (2) CY significantly promoted the apoptosis of breast cancer cells (P<0.01) . (3) CY could decrease the expression of p-Akt and increase the expression of Cleaved-Caspase-3. (4) CY impaired migration and invasion of MDA-MB-231 cells (P<0.01) , and can inhibit the expression of MMP2. Conclusion CY could promote the apoptosis of breast cancer cells through activation of apoptosis signaling, and can inhibit breast cancer cell metastasis by suppressing MMP2. And CY may be a potential therapeutic drug for human breast cancer.